High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
237.63M
+11.48%
-0.515
-39.44%
181.19M
-84.59%
-0.845
-108.42%
199.66M
+11.62%
-0.744
-10.39%
Estimates Revision
The market is revising Upward the revenue expectations for PTC Therapeutics, Inc. (PTCT) for FY2025, with the revenue forecasts being adjusted by 1.78% over the past three months. During the same period, the stock price has changed by 54.00%.
Revenue Estimates for FY2025
Revise Upward
+1.78%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+24.32%
In Past 3 Month
Stock Price
Go Up
+54.00%
In Past 3 Month
15 Analyst Rating
Wall Street analysts forecast PTCT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTCT is 76.18 USD with a low forecast of 50.00 USD and a high forecast of 118.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
4 Hold
1 Sell
Moderate Buy
Current: 76.690
Low
50.00
Averages
76.18
High
118.00
Current: 76.690
Low
50.00
Averages
76.18
High
118.00
Goldman Sachs
NULL -> Sell
downgrade
$44 -> $50
2025-11-06
Reason
Goldman Sachs
Price Target
$44 -> $50
2025-11-06
downgrade
NULL -> Sell
Reason
Goldman Sachs raised the firm's price target on PTC Therapeutics to $50 from $44 and keeps a Sell rating on the shares.
Goldman Sachs
Sell
maintain
$44 -> $50
2025-11-05
Reason
Goldman Sachs
Price Target
$44 -> $50
2025-11-05
maintain
Sell
Reason
Goldman Sachs raised the firm's price target on PTC Therapeutics to $50 from $44 and keeps a Sell rating on the shares. PTC Therapeutics reported stronger-than-expected Q3 results driven by robust early Sephience sales and solid performance from the legacy Duchenne muscular dystrophy franchise, the analyst tells investors in a research note. Sephience's launch showed encouraging momentum with broad COE engagement and favorable early payer dynamics, though DMD revenue continued to decline sequentially. While early uptake supports confidence in Sephience's trajectory, U.S. sales targets above $1B appear ambitious, and attention now turns to ongoing launch progress, the upcoming votoplam FDA update, and pipeline developments at December's R&D day, Goldman says.
TD Cowen
Joseph Thome
Hold
maintain
$50 -> $63
2025-11-05
Reason
TD Cowen
Joseph Thome
Price Target
$50 -> $63
2025-11-05
maintain
Hold
Reason
TD Cowen analyst Joseph Thome raised the firm's price target on PTC Therapeutics to $63 from $50 and keeps a Hold rating on the shares. The firm said they posted a solid topline beat where nitial Sephience sales of $19.2MM beat the $4MM consensus, and surpassed the higher end of investor expectations.
RBC Capital
Outperform
maintain
$70 -> $82
2025-11-05
Reason
RBC Capital
Price Target
$70 -> $82
2025-11-05
maintain
Outperform
Reason
RBC Capital raised the firm's price target on PTC Therapeutics to $82 from $70 and keeps an Outperform rating on the shares after its Q3 earnings beat. The company's Sephience launch appears to be off to an excellent start, likely surpassing the growing expectations into the quarter, and with signals supporting good near/medium-term durability, the analyst tells investors in a research note.
Citi
Neutral
maintain
$50 -> $75
2025-11-05
Reason
Citi
Price Target
$50 -> $75
2025-11-05
maintain
Neutral
Reason
Citi raised the firm's price target on PTC Therapeutics to $75 from $50 and keeps a Neutral rating on the shares following the Q3 report. The firm says PTC reported a strong first quarter of Sephience sales.
Barclays
Gena Wang
Equal Weight
maintain
$46 -> $68
2025-11-05
Reason
Barclays
Gena Wang
Price Target
$46 -> $68
2025-11-05
maintain
Equal Weight
Reason
Barclays analyst Gena Wang raised the firm's price target on PTC Therapeutics to $68 from $46 and keeps an Equal Weight rating on the shares following the earnings report.
See All Ratings
Valuation Metrics
The current forward P/E ratio for PTC Therapeutics Inc (PTCT.O) is -30.34, compared to its 5-year average forward P/E of -10.80. For a more detailed relative valuation and DCF analysis to assess PTC Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-10.80
Current PE
-30.34
Overvalued PE
-1.80
Undervalued PE
-19.79
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
15.28
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
210.32
Undervalued EV/EBITDA
-179.77
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
5.10
Current PS
75.60
Overvalued PS
12.38
Undervalued PS
-2.18
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 3181.08% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
PTCT News & Events
Events Timeline
(ET)
2025-11-04
16:24:54
PTC Therapeutics projects FY25 revenue between $750M and $800M, while consensus estimates stand at $1.73B.
2025-11-04
16:23:25
PTC Therapeutics Announces Q3 Earnings Per Share of 20 Cents, Falling Short of Consensus Estimate of $1.11
2025-11-03 (ET)
2025-11-03
12:05:03
Truist finds no implications for PTC and Wave Life from uniQure's announcement.
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/benzinga.png)
Preview
6.0
11-06BenzingaCitigroup Keeps Neutral Rating on PTC Therapeutics and Increases Price Target to $75
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/73bb93633e60d4444169c8a9242a26f4041cfad6ac85cc1823b4e5341467f808.jpg)
Preview
9.5
11-05NASDAQ.COMPTC Therapeutics (PTCT) Q3 Earnings Review: Analyzing Key Metrics Against Estimates
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/6f19a936996ee2b6d9db619170c11f476195dcc6c5b2a51c02e2951bac075676.png)
Preview
1.0
10-31PRnewswirePTC Therapeutics to Participate at Upcoming Investor Conferences
Sign Up For More News
People Also Watch
FAQ
What is PTC Therapeutics Inc (PTCT) stock price today?
What is PTC Therapeutics Inc (PTCT)'s business?
What is the price predicton of PTCT Stock?
What is PTC Therapeutics Inc (PTCT)'s revenue for the last quarter?
What is PTC Therapeutics Inc (PTCT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for PTC Therapeutics Inc (PTCT)'s fundamentals?
How many employees does PTC Therapeutics Inc (PTCT). have?